Leflunomide abrogates neuroinflammatory changes in a rat model of Alzheimer's disease: the role of TNF-α/NF-κB/IL-1β axis inhibition | SpringerLink
Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis
Nuclear Factor κB Signaling in Atherogenesis | Arteriosclerosis, Thrombosis, and Vascular Biology
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function | Arthritis Research & Therapy | Full Text
Leflunomide | C12H9F3N2O2 - PubChem
NF-κB activation as a pathological mechanism of septic shock and inflammation | American Journal of Physiology-Lung Cellular and Molecular Physiology
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review - ScienceDirect
Frontiers | Pathomechanisms of bone loss in rheumatoid arthritis
Inhibiting NF-κB activation by small molecules as a therapeutic strategy. - Abstract - Europe PMC
What Is Leflunomide, Cas No 75706-12-6 Guide - ECHEMI
Individualization of leflunomide dosing in rheumatoid arthritis patients | Personalized Medicine
NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis - ScienceDirect
Leflunomide activates MAPK cascade, and JNK signaling pathway... | Download Scientific Diagram
Cancers | Free Full-Text | Targeting NF-κB Signaling for Multiple Myeloma
Nuclear transcription factor-κB as a target for cancer drug development | Leukemia
Leflunomide | C12H9F3N2O2 - PubChem
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review - ScienceDirect
Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis | Nature Communications
New Drugs for Rheumatoid Arthritis | NEJM
Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study - Sun Ying, Cui Xiaomeng, Dai Xiaomin, Lin Jiang, Lv Peng, Ma Lili, Chen Rongyi, Ji Zongfei,
The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells | Leukemia
